Patent application number | Description | Published |
20080208308 | High Temperature Oxidation-Reduction Process to Form Porous Structures on a Medical Implant - A system for treating abnormalities of the cardiovascular system includes a stent having a porous therapeutic agent carrying zone comprising oxidation and reduction products of one or more metals in the stent framework. Another embodiment of the invention includes a method of manufacturing a therapeutic agent carrying stent comprising exposing a metallic stent framework to oxidizing and reducting conditions, and forming a therapeutic agent carrying zone on the surface of the stent framework that includes oxidation and reduction products of one or more metals in the stent framework. | 08-28-2008 |
20080208352 | Stent Having Controlled Porosity for Improved Ductility - An endoluminal prosthesis for placement in a body lumen of a metallic material having controlled porosity for improved ductility. The metallic material may be formed into a stent structure or a wire or sheet, which may then be formed into the stent structure. The porous network of the stent includes pores that range from nanometer scale to micron scale. The controlled porosity accommodates volume changes as well as provides a barrier to crack propagation to allow alloy steels and amorphous metal materials, which would otherwise be considered too brittle for the demands of intraventional use, to be utilized in a stent. | 08-28-2008 |
20080249599 | Stent With Therapeutic Agent Delivery Structures in Low Strain Regions - A system for treating abnormalities of the cardiovascular system includes a stent having a plurality of therapeutic agent-carrying regions and non therapeutic agent-carrying regions. The therapeutic agent-carrying regions are located within low strain regions of the stent and the non therapeutic agent-carrying regions are located within high strain regions of the stent. Another embodiment of the invention includes a method of manufacturing a therapeutic agent-carrying stent comprising forming a stent framework and applying a formulation containing one or more therapeutic agents to the stent framework while preventing the therapeutic agents from contacting the high strain regions of the stent framework. | 10-09-2008 |
20080319529 | Stent With Improved Mechanical Properties - A stent includes a central portion having a first waveform. The first waveform is wrapped around a longitudinal axis of the stent at a pitch to define a plurality of helical turns. The stent also includes an end segment connected to one end of the central portion. The end segment has a second waveform that includes a plurality of struts and a plurality of crowns. Each of the plurality of struts has a different length so that peaks of the crowns that define an end of the stent lie within a plane that is substantially perpendicular to the longitudinal axis. Cross-sectional areas of the struts having different lengths vary so that the struts move substantially uniformly during radial contraction and/or radial expansion of the stent. | 12-25-2008 |
20080319534 | Stent With Improved Mechanical Properties - A stent includes a central portion having a first waveform. The first waveform is wrapped around a longitudinal axis of the stent at a pitch to define a plurality of helical turns. The stent also includes an end segment connected to one end of the central portion. The end segment has a second waveform that includes a plurality of struts and a plurality of crowns. Each of the plurality of struts has a different length so that peaks of the crowns that define an end of the stent lie within a plane that is substantially perpendicular to the longitudinal axis. Cross-sectional areas of the struts having different lengths vary so that the struts move substantially uniformly during radial contraction and/or radial expansion of the stent. | 12-25-2008 |
20090024200 | Drug Eluting Medical Device and Method - A drug elution stent includes a stent framework and a drug elution portion disposed on the stent framework. The drug elution portion includes a first sugar layer disposed on the stent framework, at least one therapeutic agent layer disposed on the first sugar layer and a second sugar layer disposed on the at least one therapeutic agent layer. A method of manufacturing a drug elution stent includes the steps of providing a stent having a stent framework and coating at least a portion of the stent framework with a drug elution portion. The drug elution portion includes a first sugar layer disposed on the stent framework, at least one therapeutic agent layer disposed on the first sugar layer and a second sugar layer disposed on the at least one therapeutic agent layer | 01-22-2009 |
20090093871 | Medical Implant With Internal Drug Delivery System - A system for treating a vascular condition includes a catheter and a stent disposed on the catheter. The stent includes tubing having a wall defining a central lumen and a plurality of holes. The system further includes a therapeutic agent disposed within the central lumen of the tubing. A method of manufacturing a therapeutic agent carrying stent includes inserting a therapeutic agent within a therapeutic agent delivery system into the central lumen of a hollow metal tube and forming a stent framework from the hollow tube. | 04-09-2009 |
20090204203 | Bioabsorbable Stent Having a Radiopaque Marker - A bioabsorbable stent includes one or more radiopaque markers. The stent body may include a generally cylindrical body portion and a marker support for receiving the one or more marker(s). The marker support may be connected to an end of the body portion, or may be an integral portion of the body portion. By selectively controlling dissolution of the biodegradable material of the marker support, the marker support will remain intact for a sufficient time to allow for the marker to endothelialize and therefore prevent the marker from dislodging and embolizing. The controlled dissolution may be accomplished via one or more of the following mechanisms, including increasing the cross-sectional thickness of the marker support, passivating or oxidizing the marker support, utilizing a different, slower absorbing material for the marker support, utilizing a bioabsorbable polymeric coating on the marker support, or protecting the marker support with a sacrificial anode. | 08-13-2009 |
20100125325 | Stent With Cathodic Protection and Stent Delivery System - The stent with cathodic protection and stent delivery system includes a stent delivery system including a catheter; a balloon operably attached to the catheter; and a stent disposed on the balloon. The stent includes a stent body having a first stent layer of an anodic stent material disposed about a second stent layer of a cathodic stent material; and a battery having a first battery layer of an anodic battery material and a second battery layer of a cathodic battery material. The first stent layer is electrically coupled to the first battery layer and the second stent layer is electrically coupled to the second battery layer. | 05-20-2010 |
20100252470 | Packaging Systems for Percutaneously Deliverable Bioprosthetic Valves - A packaging system is disclosed for shipping a prosthetic tissue valve in a storage solution and preparing and loading of the bioprosthetic valve onto a catheter-based delivery system. The packaging system includes a fluid tight container filled with the storage solution attached to a delivery catheter, wherein the container surrounds the prosthetic tissue valve that is in a pre-loaded position on the delivery catheter during shipment and storage. The prosthetic tissue valve may include an attachment mechanism that attaches to the delivery catheter to properly position the tissue valve for loading within the delivery catheter. In another embodiment where the prosthetic tissue valve is not attached to the delivery catheter during shipment, the attachment mechanism may interact with the prosthetic tissue valve shipping container to prevent the bioprosthetic valve from moving during shipment. | 10-07-2010 |
20140046435 | STENTED TRANSCATHETER PROSTHETIC HEART VALVE DELIVERY SYSTEM AND METHOD - A percutaneous stented valve delivery device including an inner shaft, a sheath, and a delivery capsule. The sheath slidably receives the inner shaft. A capsule proximal zone is attached to the sheath. A capsule distal zone is configured to transition between normal and flared states. A diameter of the distal zone is greater in the flared state, and the capsule includes a shape memory component that naturally assumes the normal state. The device is operable to perform a reversible partial deployment procedure in which a portion of the prosthesis is exposed distal the capsule and allowed to radially expand. Subsequently, with distal advancement of the capsule, the distal zone transitions to the flared state and imparts a collapsing force onto the prosthesis, causing the prosthesis to radially collapse and become recaptured within the delivery capsule. The capsule can include a laser cut tube encapsulated by a polymer. | 02-13-2014 |